607 related articles for article (PubMed ID: 2944965)
1. Interleukin 2-activated human killer cells are derived from phenotypically heterogeneous precursors.
Damle NK; Doyle LV; Bradley EC
J Immunol; 1986 Nov; 137(9):2814-22. PubMed ID: 2944965
[TBL] [Abstract][Full Text] [Related]
2. Human lymphokine-activated killer (LAK) cells: identification of two types of effector cells.
Tilden AB; Itoh K; Balch CM
J Immunol; 1987 Feb; 138(4):1068-73. PubMed ID: 3100627
[TBL] [Abstract][Full Text] [Related]
3. Interleukin 2-activated human lymphocytes exhibit enhanced adhesion to normal vascular endothelial cells and cause their lysis.
Damle NK; Doyle LV; Bender JR; Bradley EC
J Immunol; 1987 Mar; 138(6):1779-85. PubMed ID: 3493287
[TBL] [Abstract][Full Text] [Related]
4. Immunoregulatory T lymphocytes in man. Soluble antigen-specific suppressor-inducer T lymphocytes are derived from the CD4+CD45R-p80+ subpopulation.
Damle NK; Childs AL; Doyle LV
J Immunol; 1987 Sep; 139(5):1501-8. PubMed ID: 2887618
[TBL] [Abstract][Full Text] [Related]
5. Lymphokine-activated killer activity in long-term cultures with anti-CD3 plus interleukin 2: identification and isolation of effector subsets.
Ochoa AC; Hasz DE; Rezonzew R; Anderson PM; Bach FH
Cancer Res; 1989 Feb; 49(4):963-8. PubMed ID: 2521457
[TBL] [Abstract][Full Text] [Related]
6. CD8+CD11b+ peripheral blood T lymphocytes contain lymphokine-activated killer cell precursors.
Dianzani U; Zarcone D; Pistoia V; Grossi CE; Pileri A; Massaia M; Ferrarini M
Eur J Immunol; 1989 Jun; 19(6):1037-44. PubMed ID: 2502419
[TBL] [Abstract][Full Text] [Related]
7. In vivo effects of recombinant IL-2. I. Isolation of circulating Leu-19+ lymphokine-activated killer effector cells from cancer patients receiving recombinant IL-2.
McMannis JD; Fisher RI; Creekmore SP; Braun DP; Harris JE; Ellis TM
J Immunol; 1988 Feb; 140(4):1335-40. PubMed ID: 3257776
[TBL] [Abstract][Full Text] [Related]
8. Lysis of tumor cells by CD3+4-8-16+ T cell receptor alpha beta- clones, regulated via CD3 and CD16 activation sites, recombinant interleukin 2, and interferon beta 1.
van de Griend RJ; Tax WJ; van Krimpen BA; Vreugdenhil RJ; Ronteltap CP; Bolhuis RL
J Immunol; 1987 Mar; 138(5):1627-33. PubMed ID: 2949018
[TBL] [Abstract][Full Text] [Related]
9. Phenotypic and functional characterization of recombinant interleukin 2 (rIL 2)-induced activated killer cells: analysis at the population and clonal levels.
Ferrini S; Miescher S; Zocchi MR; von Fliedner V; Moretta A
J Immunol; 1987 Feb; 138(4):1297-302. PubMed ID: 3100633
[TBL] [Abstract][Full Text] [Related]
10. Functional characterization of human T lymphocyte subsets distinguished by monoclonal anti-leu-8.
Kansas GS; Wood GS; Fishwild DM; Engleman EG
J Immunol; 1985 May; 134(5):2995-3002. PubMed ID: 3156924
[TBL] [Abstract][Full Text] [Related]
11. The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes.
Lanier LL; Le AM; Civin CI; Loken MR; Phillips JH
J Immunol; 1986 Jun; 136(12):4480-6. PubMed ID: 3086432
[TBL] [Abstract][Full Text] [Related]
12. Generation of lymphokine-activated killer cell activity from human thymocytes.
Ramsdell FJ; Golub SH
J Immunol; 1987 Sep; 139(5):1446-53. PubMed ID: 2442246
[TBL] [Abstract][Full Text] [Related]
13. Analysis of the murine lymphokine-activated killer (LAK) cell phenomenon: dissection of effectors and progenitors into NK- and T-like cells.
Kalland T; Belfrage H; Bhiladvala P; Hedlund G
J Immunol; 1987 Jun; 138(11):3640-5. PubMed ID: 3495566
[TBL] [Abstract][Full Text] [Related]
14. The expression and functional involvement of laminin-like molecules in non-MHC restricted cytotoxicity by human Leu-19+/CD3- natural killer lymphocytes.
Schwarz RE; Hiserodt JC
J Immunol; 1988 Nov; 141(10):3318-23. PubMed ID: 3263421
[TBL] [Abstract][Full Text] [Related]
15. Recombinant interleukin 2 enhanced natural killer cell-mediated cytotoxicity in human lymphocyte subpopulations expressing the Leu 7 and Leu 11 antigens.
Lanier LL; Benike CJ; Phillips JH; Engleman EG
J Immunol; 1985 Feb; 134(2):794-801. PubMed ID: 3871216
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-2- and mitogen-activated NK-like killer cells from highly purified human peripheral blood T cell (CD3+ N901-) cultures.
Atzpodien J; Wisniewski D; Gulati S; Welte K; Knowles R; Clarkson B
Nat Immun Cell Growth Regul; 1987; 6(3):129-40. PubMed ID: 3114621
[TBL] [Abstract][Full Text] [Related]
17. Precursor phenotype of lymphokine-activated killer cells in the mouse.
Salup RR; Mathieson BJ; Wiltrout RH
J Immunol; 1987 Jun; 138(11):3635-9. PubMed ID: 3108370
[TBL] [Abstract][Full Text] [Related]
18. IL-4-induced lymphokine-activated killer cells. Lytic activity is mediated by phenotypically distinct natural killer-like and T cell-like large granular lymphocytes.
Peace DJ; Kern DE; Schultz KR; Greenberg PD; Cheever MA
J Immunol; 1988 May; 140(10):3679-85. PubMed ID: 2896213
[TBL] [Abstract][Full Text] [Related]
19. Induction of murine lymphokine-activated killer cells by recombinant IL-7.
Lynch DH; Miller RE
J Immunol; 1990 Sep; 145(6):1983-90. PubMed ID: 1975262
[TBL] [Abstract][Full Text] [Related]
20. Mode of in vitro augmentation of natural killer cell activity by recombinant human interleukin 2: a comparative study of Leu-11+ and Leu-11- cell populations in cord blood and adult peripheral blood.
Seki H; Ueno Y; Taga K; Matsuda A; Miyawaki T; Taniguchi N
J Immunol; 1985 Oct; 135(4):2351-6. PubMed ID: 3928745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
